Shedding light on brain oxygenation

Summary

Our research group, led by Dr. Jeff Dunn, has identified low oxygen levels – a condition known as hypoxia, in the brain of 33% of people with Multiple Sclerosis (MS). We are currently conducting a research study to explore how hypoxia relates to symptoms, brain function, and progression.

We apply safe, non-invasive techniques, including near-infrared spectroscopy (NIRS) and electroencephalography (EEG), to measure brain oxygen levels and function. We also conduct MRI scans and collect a blood sample to identify physiological markers, such as inflammation, changes in brain structure and blood flow, and disease progression, as indicated by lesion load and brain atrophy.
All techniques used in our study are safe. Participants may choose to take part in one or more components of the study.

By comparing results from healthy participants and participants with MS, we aim to better understand how changes in brain oxygen and physiology may be linked to brain function and disease progression.

If you are interested in learning more, please fill out the short form below. Our research team will contact you to discuss the study and review eligibility criteria.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 75

Accepts healthy participants: Yes

Inclusion criteria:

Age 18-75
Men and women
Clinical diagnosis of MS
Non-smoker (Nicotine or Marijuana)

Selection criteria - Healthy Participants:
Age 18-75
Men and women
Non-smoker (Nicotine or Marijuana)
No recent systemic infection
Otherwise healthy
No history of cardiovascular/vascular disease

Participate

Fill out the following form if you want to participate in this research

Method of contact

UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is committed to ensuring the privacy of all students, staff, and community members. Your personal information is being collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used and disclosed for the purposes outlined in UCalgary’s Notice of Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s Privacy Management Program. Your personal information may be input into automated systems to generate content or make decisions, recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection, use, or disclosure of your personal information, please contact accessandprivacy@ucalgary.ca.

Additional information

Contact information

If you are interested in participating in this study, or if you would like more information, please contact us at 403-2207849

Principal investigator:

Jeffrey Frank Dunn

Clinical trial:

No

REB-ID:

REB19-1105